Chinese Prescription Kangen-karyu as Potential Anti-Alzheimer’s Disease Therapeutic: Analyses of BACE1 and GSK-3b Inhibitory Activities

Updata:01-01-1970

Source:
By:Chan Hum Park

DOI: https://doi.org/10.30564/jim.v10i2.3441

Abstract:

Inhibition of β-site amyloid precursor protein-cleaving enzyme 1 (BACE1) or glycogen synthase kinase-3β (GSK-3β) is estimated to be the central therapeutic approach for Alzheimer’s disease (AD). In this study, water extract of Kangenkaryu, its crude drug and chemical composition used in oriental medicine were evaluated regarding their BACE1 and GSK-3β inhibitory activities.Fluorescence resonance energy transfer was used to characterize the BACE1 inhibitory effect of Kangen-karyu, its crude drug and chemical composition.GSK-3β activity was determined using the Kinase-Glo Luminescent Kinase Assay Platform. The water extract of Kangen-karyu inhibited BACE1 and GSK-3β in concentration-dependent manners when compared with reference drugs, quercetin and luteolin. Among six components of Kangen-karyu, the water extracts of Salviae Miltiorrhizae Radix or Cyperi Rhizoma exhibited significant inhibitory effects on BACE1 and GSK-3β. Among the constituents of Salviae Miltiorrhizae Radix extract, salvianolic acid C, salvianolic acid A, rosmarinic acid, and magnesium lithospermate B significantly inhibited BACE1. In addition, they inhibited GSK-3β with an IC50 value range of 6.97 to 135.35 μM. From these results, one of the effectiveness and its mechanisms of action of Kangen-karyu against AD may be the inhibition of BACE1 and GSK-3β, and one of the active ingredients of Kangen-karyu is Salviae Miltiorrhizae Radix and its constituents.

References:

[1] Duyckaerts C, Delatour B, Potier MC. Classification and basic pathology of Alzheimer disease. Acta Neuropathol 2009;118(1): 5-36. [2] Hardy J, Selkoe D. The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science 2002;297(5580):353-6. [3] Vassar R, Bennett BD, Babu-Khan S, Kahn S, Meddiaz EA, Denis P, Teplow DB, Ross S, Amarante P, Loeloff R, Luo Y, Fisher S, Fuller J, Edenson S, Lile J, Jarosinski MA, Biere AL, Curran E, Burgess T, Louis JC, Collins F, Treanor J, Rogers G, Citron M. β-Secretase cleavage of Alzheimer’s amyloid precursor protein by the transmembrane aspartic protease BACE. Science 1999;286(5440):735-41. [4] Vassar R, Kuhn PH, Haass C, Kennedy ME, Rajendran L, Wong PC, Lichtenthaler SF. Function, therapeutic potential and cell biology of BACE proteases: current status and future prospects. J Neurochem 2014;130(1):4-28. [5] Hoover BR, Reed MN, Su J, Penrod RD, Kotilinek LA, Grant MK, Pitstick R, Carlson GA, Lanier LM, Yuan LL, Ashe KH, Liao D. Tau mislocalization to dendritic spines mediates synaptic dysfunction independently of neurodegeneration. Neuron 2010;68(6):1067-81. [6] Liang Z, Li QX. Discovery of selective, substrate-competitive, and passive membrane permeable glycogen synthase kinase-3β inhibitors: synthesis, biological evaluation, and molecular modeling of new C-glycosylflavones. ACS Chem Neurosci 2018;9(5):1166-83. [7] Yokozawa T, Park CH, Matsumoto K. Scientific evidence for therapeutic effects of Chinese prescription Kangen-karyu from pre-clinical animal experiments. Drug Discov Ther 2017;11(1):6-14. [8] Zhao Q, Yokozawa T, Yamabe N, Tsuneyama K, Li X, Matsumoto K. Kangen-karyu improves memory deficit caused by aging through normalization of neuro-plasticity-related signaling system and VEGF system in the brain. J Ethnopharmacol 2010;131(2):377-85. [9] Satoh A, Yokozawa T, Cho EJ, Okamoto T, Sei Y. Antioxidative effects related to the potential anti-aging properties of the Chinese prescription Kangen-karyu and Carthami Flos in senescence-accelerated mice. Arch Gerontol Geriatr 2004;39(1):69-82. [10] Kim HY, Okamoto T, Yokozawa T. Beneficial effects of Chinese prescription Kangen-karyu on diabetes associated with hyperlipidemia, advanced glycation endproducts, and oxidative stress in streptozotocin-induced diabetic rats. J Ethnopharmacol 2009;124(2):263-9. [11] Park CH, Noh JS, Yamabe N, Okamoto T, Kang KS, Zhao Q, Matsumoto K, Shibahara N, Yokozawa T.Renoprotective effect of Kangen-karyu on the development of diabetic nephropathy in type 2 diabetic db/db mice. J Trad Med 2010;27(5+6):192-203. [12] Pu F, Motohashi K, Kaneko T, Tanaka Y, Manome N, Irie K, Takata J, Egashira N, Oishi R, Okamoto T, Sei Y, Yokozawa T, Mishima K, Iwasaki K, Fujiwara M. Neuroprotective effects of Kangen-karyu on spatial memory impairment in an 8-arm radial maze and neuronal death in the hippocampal CA1 region induced by repeated cerebral ischemia in rats. J Pharmacol Sci 2009;109(3):424-30. [13] Parsons C, Danysz W, Dekundy A, Pulte I. Memantine and cholinesterase inhibitors: complementary mechanisms in the treatment of Alzheimer’s disease. Neurotox Res 2013;24(3):358-69. [14] Wilkinson D, Andersen HF. Analysis of the effect of memantine in reducing the worsening of clinical symptoms in patients with moderate to severe Alzheimer’s disease. Dement Geriatr Cogn Disord 2007;24(2):138-45. [15] Markesbery WR. Oxidative stress hypothesis in Alzheimer’s disease. Free Radic Biol Med 1997;23(1):134-47. [16] Torreilles F, Salman-Tabcheh S, Guérin M, Torreilles J. Neurodegenerative disorders: the role of peroxynitrite. Brain Res Rev 1999;30(2):153-63. [17] Butterfield DA, Reed T, Newman SF, Sultana R. Roles of amyloid β-peptide-associated oxidative stress and brain protein modifications in the pathogenesis of Alzheimer’s disease and mild cognitive impairment. Free Radic Biol Med 2007;43(5):658-77. [18] Smith MA, Richey PL, Taneda S, Kutty RK, Sayre LM, Monnier VM, Perry G. Advanced maillard reaction end products, free radicals, and protein oxidation in Alzheimer’s disease. Ann NY Acad Sci 1994;738(1):447-54. [19] Ischiropoulos H. Biological tyrosine nitration: a pathophysiological function of nitric oxide and reactive oxygen species. Arch Biochem Biophys 1998;356(1):1-11. [20] Aliev G, Obrenovich ME, Reddy VP, Shenk JC, Moreira PI, Nunomura A, Zhu X, Smith MA, Perry G. Antioxidant therapy in Alzheimer’s disease: theory and practice. Mini Rev Med Chem 2008;8(13):1395-406. [21] Feng Y, Wang X. Antioxidant therapies for Alzheimer’s disease. Oxid Med Cell Longev 2012;2012:article ID472932. [22] Mecocci P, Polidori MC. Antioxidant clinical trials in mild cognitive impairment and Alzheimer’s disease. Biochim Biophys Acta 2012;1822(5):631-8. [23] Teixeira J, Silva T, Andrade PB, Borges F. Alzheimer’s disease and antioxidant therapy: how long how far? Curr Med Chem 2013;20(24):2939-52. [24] Yokozawa T, Kim YA, Kim HY, Okamoto T, Sei Y. Protective effect of the Chinese prescription Kangen-karyu against high glucose-induced oxidative stress in LLC-PK1 cells. J Ethnopharmacol 2007;109(1):113-20. [25] Chen J, Lee FSC, Li L, Yang B, Wang X. Standardized extracts of Chinese medicinal herbs: case study of Danshen (Salvia miltiorrhiza Bunge). J Food Drug Anal 2007;15:347-64. [26] Shen J, Yang K, Sun C, Zheng M. Analysis of active components in Salvia miltiorrhiza injection based on vascular endothelial cells protection. Acta Pharm 2014;64(3):325-34. [27] Liu HY, Wan P, Niu M, Liu Q, Zhang YQ, Zhang ZY. Autotoxins screening from aqueous extracts of Salvia miltiorrhiza Bge. based on spectrum-effect relationship between HPLC fingerprints and autotoxicity. Pak J Bot 2016;48(4):1467-71.

Tags: